Advertisement
UK markets open in 1 hour 55 minutes

  • NIKKEI 225

    37,696.93
    -763.15 (-1.98%)
     

  • HANG SENG

    17,295.93
    +94.66 (+0.55%)
     

  • CRUDE OIL

    82.90
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,327.30
    -11.10 (-0.47%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • Bitcoin GBP

    51,546.83
    -2,230.65 (-4.15%)
     

  • CMC Crypto 200

    1,390.14
    -33.96 (-2.38%)
     

  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

AstraZeneca lung cancer drug delays disease by more than a year

Reuters - UK Focus

LONDON, April 17 (Reuters) - An experimental lung cancer pill from AstraZeneca (NYSE: AZN - news) delays disease progression by more than a year, according to new data presented at a medical meeting on Friday.

AZD9291, which the company expects to file for U.S. approval in the second quarter of 2015, is one of a number of cancer medicines AstraZeneca is hoping will rebuild its sales following patent losses on older drugs.

An analysis presented at the European Lung Cancer Conference in Geneva demonstrated a median progression-free survival for patients on the drug of 13.5 months.

AZD9291, like a rival product in development at Clovis Oncology, targets a genetic mutation that helps tumours evade current lung cancer pills, including AstraZeneca's own established product Iressa.

During its defence against a $118 billion takeover attempt by Pfizer (NYSE: PFE - news) last year, AstraZeneca said it believed AZD9291 could sell as much as $3 billion a year. (Reporting by Ben Hirschler. Editing by Jane Merriman)